Induction Carboplatin

Phase 2Small molecule

Radiation Therapy Oncology Group

Induction Carboplatin is one of 6 small molecule programs targeting First Line Therapy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

First Line TherapyRecruiting

First Line TherapyPhase 2

Recruiting

Competition

Competitive Landscape

6 competitors in First Line Therapy

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

6 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

7 3

Zepzelca

Jazz Pharmaceuticals

Phase 2

1 4

Xpovio

KKaryopharm Therapeutics Inc

Phase 2

1 5

HB0025

SShanghai Huaota Biopharmaceutical Co., Ltd.

Phase 2

1 6

Induction Carboplatin

Radiation Therapy Oncology Group

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

First Line Therapy

NCT06667167

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00096226·60 enrolled

First Line Therapy1 trial

First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy

Recruiting·NNir Peled·Phase 2·NCT06667167·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Induction Carboplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Induction Carboplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Induction Carboplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Radiation Therapy Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Radiation Therapy Oncology Group

Induction Carboplatin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

First Line Therapy1 trial

References

Drug Info

Quick Facts

Related News